Cargando…

Beta-blocker Rebound Phenomenon in an Adolescent with Graves’ Disease

Detalles Bibliográficos
Autor principal:	Anık, Ahmet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724061/ https://www.ncbi.nlm.nih.gov/pubmed/35859995 http://dx.doi.org/10.4274/jcrpe.galenos.2022.2022-6-2

Ejemplares similares

COVID-19 Pandemic and Possible Rebound Phenomenon in Incidence of Acute Myocardial Infarction
por: Čulić, Viktor, et al.
Publicado: (2021)

Reply to Čulić et al—COVID-19 Pandemic and Possible Rebound Phenomenon in Incidence of Acute Myocardial Infarction
por: Fardman, Alexander, et al.
Publicado: (2021)

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
por: Kim, Albert S., et al.
Publicado: (2022)

Early prophylaxis of cardiomyopathy with beta-blockers and angiotensin receptor blockers in patients with Duchenne muscular dystrophy
por: Lee, Heirim, et al.
Publicado: (2022)

Response to: A myth of ophthalmic beta-blockers therapy
por: Wolfs, Roger C. W.
Publicado: (2009)

Disease-modifying medications in heart failure: more than ACE inhibitors and beta blockers
por: Chao, Chia-Ter
Publicado: (2011)

Dangers in using beta-blockers in patients with venovenous extracorporeal membrane oxygenation
por: Álvarez, Diego Rodríguez, et al.
Publicado: (2022)

Unilateral Graves' Disease
por: Mahalakshmi, VNSSVAMS D, et al.
Publicado: (2019)

Is the use of non-selective beta-blockers necessary in cirrhotic patients with small varices?
por: Qi, Xingshun, et al.
Publicado: (2014)

Effectiveness and safety of four different beta‐blockers in patients with chronic heart failure
por: Liu, Baoshan, et al.
Publicado: (2023)

Post COVID-19 Acute Myocardial Infarction Rebound
por: Fardman, Alexander, et al.
Publicado: (2020)

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
por: Anastasilakis, Athanasios D., et al.
Publicado: (2021)

Puberty Blockers and Suicidality in Adolescents Suffering from Gender Dysphoria
por: Biggs, Michael
Publicado: (2020)

Using the rebound tonometer to measure intraocular pressure in an anesthetized patient
por: Jethani, Jitendra
Publicado: (2014)

Raynaud’s phenomenon
por: Solomons, HD
Publicado: (2011)

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022)

Atrioventricular block after reperfusion: A reflection on early beta-blocker therapy for acute myocardial infarction
por: Zhong, Yue, et al.
Publicado: (2017)

Graves' disease presenting with acute renal infarction
por: Baek, Cho-Ok, et al.
Publicado: (2014)

Beta-Blockers in COVID-ARDS: Inflammation or Hemodynamic?
por: de Roquetaillade, Charles, et al.
Publicado: (2022)

Comment on ‘Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma'
por: Ji, Y, et al.
Publicado: (2013)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

Evaluation of Goldmann applanation tonometry, rebound tonometry and dynamic contour tonometry in keratoconus
por: De Bernardo, Maddalena, et al.
Publicado: (2018)

Comment on: Rebound inflammation after an intravitreal injection in Vogt–Koyanagi–Harada syndrome
por: Jain, Manish
Publicado: (2018)

Relapse in the first 8 weeks after onset of COVID-19 disease in outpatients: Viral reactivation or inflammatory rebound?
por: Buskermolen, Maaike, et al.
Publicado: (2021)

A Postoperative Phenomenon of Percutaneous Endoscopic Lumbar Discectomy: Rebound Pain
por: Zhang, Chang, et al.
Publicado: (2021)

Is heart rate reduction more important than target dose in chronic heart failure therapy with a beta-blocker?
por: Guo, Yong-Fang, et al.
Publicado: (2011)

Bone Fracture in an Adolescent: Just Tip of the Iceberg in Metabolic Bone Disease
por: Anık, Ahmet
Publicado: (2022)

Response to comment on: Rebound inflammation after an intravitreal injection in Vogt–Koyanagi–Harada syndrome
por: Ranjan, Richa, et al.
Publicado: (2018)

Unmasking of Neuropsychiatric Manifestations after Total Thyroidectomy for Graves' Disease
por: Pradhan, Roma, et al.
Publicado: (2018)

Graves’ disease following SARS-CoV-2 vaccination
por: Sriphrapradang, Chutintorn, et al.
Publicado: (2021)

Sexuality is a Natural Phenomenon
por: Gupta, Harish, et al.
Publicado: (2022)

The sparing phenomenon of cutaneous amyloidosis
por: Zhou, Hui-Wen, et al.
Publicado: (2021)

Head rebound test in the clinical neurological examination of veterinary patients: a case example and discussion of Stewart and Holmes’ rebound phenomenon
por: Santifort, Koen M.
Publicado: (2023)

Reply: Comment on ‘Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma' – β-blockers are potent anti-angiogenic and chemo-sensitising agents, rather than cytotoxic drugs
por: Pasquier, E, et al.
Publicado: (2013)

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?
por: Gousseff, Marie, et al.
Publicado: (2020)

A Rare Phenomenon of Hashimotos Thyroiditis Converting to Graves Disease
por: Caseja, Ahl Jeffrey, et al.
Publicado: (2021)

Thyroidectomy and uncontrolled graves’ disease – Multidisciplinary approach prevents unnecessary cancellation
por: Kumar, Chandra M.
Publicado: (2022)

Graves' disease with thyroid hemiagenesis: A rare abnormality with rarer presentation
por: Philip, Rajeev, et al.
Publicado: (2014)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

C-Mac guided bronchial blocker (COOPDECH™) insertion for one lung ventilation in an adolescent with difficult airway
por: Hariharan, Uma, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_unoifshl288rkee1jl00tvdma1